Prostaglandin I2-IP signalling regulates human Th17 and treg cell differentiation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 5, 2013, Pages 335-344

  Liu, Wenxuan ^a   Li, Hui ^a   Zhang, Xiaojing ^a   Wen, Di ^a   Yu, Feng ^a   Yang, Shengchang ^a   Jia, Xianxian ^a   Cong, Bin ^a   Ma, Chunling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Foxp3; Prostaglandin I2; Regulatory T cells; RORC; Th17 cells

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ILOPROST; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; ANTITHROMBOCYTIC AGENT; BUCLADESINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; ISOQUINOLINE DERIVATIVE; N (2 (4 BROMOCINNAMYLAMINO)ETHYL) 5 ISOQUINOLINESULFONAMIDE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; RORC PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; SULFONAMIDE;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH17 CELL; UPREGULATION; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FOXP3; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PROSTAGLANDIN I(2); RORC;

FOXP3; PROSTAGLANDIN I(2); REGULATORY T CELLS; RORC; TH17 CELLS;

BUCLADESINE; CELL DIFFERENTIATION; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EPOPROSTENOL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; ILOPROST; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-6; ISOQUINOLINES; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, EPOPROSTENOL; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; SULFONAMIDES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84886950684     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.08.006     Document Type: Article

References (44)

1. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 2007, 148:32-46.
2. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
3. Weaver C.T., Hatton R.D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat. Rev. Immunol. 2009, 9:883-889.
4. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10:490-500.
5. Xu L., Kitani A., Strober W. Molecular mechanisms regulating TGF-beta-induced Foxp3 expression. Mucosal Immunol. 2010, 3:230-238.
6. + regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. 2009, 10:689-695.
7. Zhou X., Bailey-Bucktrout S., Jeker L.T., Bluestone J.A. Plasticity of CD4(+) FoxP3(+) T cells. Curr. Opin. Immunol. 2009, 21:281-285.
8. Matsuoka T., Narumiya S. The roles of prostanoids in infection and sickness behaviors. J. Infect. Chemother. 2008, 14:270-278.
9. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 1997, 15:297-322.
10. Kabashima K., Miyachi Y. Prostanoids in the cutaneous immune response. J. Dermatol. Sci. 2004, 34:177-184.
11. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 1999, 79:1193-1226.
12. Honda T., Segi-Nishida E., Miyachi Y., Narumiya S. Prostacyclin-IP signalling and prostaglandin E2-EP2/EP4 signalling both mediate joint inflammation in mouse collagen-induced arthritis. J. Exp. Med. 2006, 203:325-335.
13. Sheibanie A.F., Yen J.H., Khayrullina T., Emig F., Zhang M., Tuma R., Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis. J. Immunol. 2007, 178:8138-8147.
14. Sheibanie A.F., Khayrullina T., Safadi F.F., Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum. 2007, 56:2608-2619.
15. Boniface K., Bak-Jensen K.S., Li Y., Blumenschein W.M., McGeachy M.J., McClanahan T.K., McKenzie B.S., Kastelein R.A., Cua D.J., de Waal Malefyt R. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signalling. J. Exp. Med. 2009, 206:535-548.
16. Hillyer P., Larche M.J., Bowman E.P., McClanahan T.K., de Waal Malefyt R., Schewitz L.P., Giddins G., Feldmann M., Kastelein R.A., Brennan F.M. Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1581-1589.
17. Chen H., Qin J., Wei P., Zhang J., Li Q., Fu L., Li S., Ma C., Cong B. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukot. Essent. Fatty Acids 2009, 80:195-200.
18. Boswell M.G., Zhou W., Newcomb D.C., Peebles R.S. PGI2 as a regulator of CD4+ subset differentiation and function. Prostaglandins Other Lipid Mediat. 2011, 96:21-26.
19. Li H., Bradbury J.A., Dackor R.T., Edin M.L., Graves J.P., DeGraff L.M., Wang P.M., Bortner C.D., Maruoka S., Lih F.B., Cook D.N., Tomer K.B., Jetten A.M., Zeldin D.C. Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation. Am. J. Respir. Crit. Care Med. 2011, 184:37-49.
20. Truchetet M.E., Allanore Y., Montanari E., Chizzolini C., Brembilla N.C. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Ann. Rheum. Dis. 2012, 71:2044-2050.
21. Zhou W., Dowell D.R., Huckabee M.M., Newcomb D.C., Boswell M.G., Goleniewska K., Lotz M.T., Toki S., Yin H., Yao S., Natarajan C., Wu P., Sriram S., Breyer R.M., Fitzgerald G.A., Peebles R.S. Prostaglandin I2 signalling drives Th17 differentiation and exacerbates experimental autoimmune encephalomyelitis. PLoS One 2012, 7:e33518.
22. Boie Y., Rushmore T.H., Darmon-Goodwin A., Grygorczyk R., Slipetz D.M., Metters K.M., Abramovitz M. Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem. 1994, 269:12173-12178.
23. Nakagawa O., Tanaka I., Usui T., Harada M., Sasaki Y., Itoh H., Yoshimasa T., Namba T., Narumiya S., Nakao K. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 1994, 90:1643-1647.
24. Moncada S., Vane J.R. The role of prostacyclin in vascular tissue. Fed. Proc. 1979, 38:66-71.
25. Nakajima S., Honda T., Sakata D., Egawa G., Tanizaki H., Otsuka A., Moniaga C.S., Watanabe T., Miyachi Y., Narumiya S., Kabashima K. Prostaglandin I2-IP signalling promotes Th1 differentiation in a mouse model of contact hypersensitivity. J. Immunol. 2011, 184:5595-5603.
26. Hirahara K., Ghoreschi K., Laurence A., Yang X.P., Kanno Y., O'Shea J.J. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine. Growth Factor Rev. 2010, 21:425-434.
27. Haiqi H., Yong Z., Yi L. Transcriptional regulation of Foxp3 in regulatory T cells. Immunobiology 2011, 216:678-685.
28. Chen Z, Tato C.M., Muul L., Laurence A., O'Shea J.J. Distinct Regulation of Interleukin-1 Human T Helper Lymphocytes. Arthritis Rheum. 2007, 56:2936-2946.
29. De Muth J.E. Basic Statistics and Pharmaceutical Statistical Applications 2006, 229-259. Chapman and Hall/CRC, Boca Raton, FL. 2nd ed.
30. Kolenko V., Rayman P., Roy B., Cathcart M.K., O'Shea J., Tubbs R., Rybicki L., Bukowski R., Finke J. Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signalling pathway. Blood 1999, 93:2308-2318.
31. Frias M.A., Rebsamen M.C., Gerber-Wicht C., Lang U. Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: a role in cardiac hypertrophy. Cardiovasc. Res. 2007, 73:57-65.
32. Jaffar Z., Wan K.S., Roberts K. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J. Immunol. 2002, 169:5997-6004.
33. Takahashi Y., Tokuoka S., Masuda T., Hirano Y., Nagao M., Tanaka H., Inagaki N., Narumiya S., Nagai H. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br. J. Pharmacol. 2002, 137:315-322.
34. Jaffar Z., Ferrini M.E., Shaw P.K., FitzGerald G.A., Roberts K. Prostaglandin I(2)promotes the development of IL-17-producing gammadelta T cells that associate with the epithelium during allergic lung inflammation. J. Immunol. 2011, 187:5380-5391.
35. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 2009, 11:625-630.
36. Muller T., Durk T., Blumenthal B., Herouy Y., Sorichter S., Grimm M., Panther E., Cicko S., Norgauer J., Idzko M. Iloprost has potent anti-inflammatory properties on human monocyte-derived dendritic cells. Clin. Exp. Allergy 2010, 40:1214-1221.
37. Zhou W., Blackwell T.S., Goleniewska K., O'Neal J.F., Fitzgerald G.A., Lucitt M., Breyer R.M., Peebles R.S. Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J. Leukoc. Biol. 2007, 81:809-817.
38. Abramovitz M., Adam M., Boie Y., Carriere M., Denis D., Godbout C., Lamontagne S., Rochette C., Sawyer N., Tremblay N.M., Belley M., Gallant M., Dufresne C., Gareau Y., Ruel R., Juteau H., Labelle M., Ouimet N., Metters K.M. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta. 2000, 1483:285-293.
39. Passerini L., Allan S.E., Battaglia M., Di Nunzio S., Alstad A.N., Levings M.K., Roncarolo M.G., Bacchetta R. STAT5-signalling cytokines regulate the expression of FOXP3 in CD4+CD25+regulatory T cells and CD4+CD25- effector T cells. Int. Immunol. 2008, 20:421-431.
40. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
41. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
42. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., Weaver C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
43. Burchill M.A., Yang J., Vogtenhuber C., Blazar B.R., Farrar M.A. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 2007, 178:280-290.
44. Ju J.H., Heo Y.J., Cho M.L., Jhun J.Y., Park J.S., Lee S.Y., Oh H.J., Moon S.J., Kwok S.K., Park K.S., Park S.H., Kim H.Y. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum. 2012, 64:3543-3552.